S
TSHA icon

SignatureFD’s Taysha Gene Therapies TSHA Stock Holding History

SignatureFD’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.81K Hold
266
– – ﹤0.01% 3151
2026
Q1 		$1.19K Buy
266
+206
+343% +$958 ﹤0.01% 3170
2025
Q4 		$330 Buy
+60
New +$291 ﹤0.01% 3267
2025
Q2 		– Sell
-553
Closed -$769 – 3432
2025
Q1 		$769 Buy
553
+271
+96% +$453 ﹤0.01% 3100
2024
Q4 		$488 Buy
282
+107
+61% +$222 ﹤0.01% 3143
2024
Q3 		$352 Buy
+175
New +$384 ﹤0.01% 3136
2024
Q1 		– Sell
-50
Closed -$89 – 3260
2023
Q4 		$89 Buy
+50
New +$100 ﹤0.01% 3088
2022
Q2 		– Sell
-165
Closed -$1K – 3348
2022
Q1 		$1K Buy
+165
New +$1.23K ﹤0.01% 3070

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SignatureFD's TSHA Position: Q2 2026 in Review

SignatureFD held its Taysha Gene Therapies (TSHA) position steady in Q2 2026 at 266 shares worth $1.81K. The position accounts for ﹤0.01% of the portfolio, ranked #3151.

SignatureFD first reported a position in TSHA in Q1 2022 and has held it in 8 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • SignatureFD held 266 shares of Taysha Gene Therapies worth $1.81K as of Q2 2026.
  • SignatureFD left its Taysha Gene Therapies share count unchanged in Q2 2026.
  • Taysha Gene Therapies made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #3151 holding.
  • SignatureFD first reported a position in Taysha Gene Therapies in Q1 2022 and has held it in 8 quarters since.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.